Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. CIP2A is a target of bortezomib in human triple negative breast cancer cells
 
  • Details

CIP2A is a target of bortezomib in human triple negative breast cancer cells

Journal
Breast Cancer Research
Journal Volume
14
Journal Issue
2
Date Issued
2012
Author(s)
Kuen-Feng Chen 
DOI
10.1186/bcr3175
URI
http://www.scopus.com/inward/record.url?eid=2-s2.0-84860130283&partnerID=MN8TOARS
http://scholars.lib.ntu.edu.tw/handle/123456789/368289
Abstract
Introduction: Triple negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic targets, such as hormone receptors or human epidermal growth factor receptor type 2 (HER2); therefore, prognosis is poor. Bortezomib, a proteasome inhibitor, may exert efficacy in TNBC through its multiple cellular effects. Here, we tested the efficacy of bortezomib and examined the drug mechanism in breast cancer cells.Methods: Five breast cancer cell lines: TNBC HCC-1937, MDA-MB-231, and MDA-MB-468; HER2-overexpressing MDA-MB-453; and estrogen receptor positive MCF-7 were used for in vitro studies. Apoptosis was examined by both flow cytometry and Western Blot. Signal transduction pathways in cells were assessed by Western Blot. Gene silencing was done by small interfering RNA (siRNA). In vivo efficacy of bortezomib was tested in nude mice with breast cancer xenografts. Immunohistochemical study was performed on tumor tissues from patients with TNBC.Results: Bortezomib induced significant apoptosis, which was independent of its proteasome inhibition, in the three TNBC cell lines, but not in MDA-MB-453 or MCF-7 cells. Furthermore, cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein phosphatase 2A (PP2A), mediated the apoptotic effect of bortezomib. We showed that bortezomib inhibited CIP2A in association with p-Akt downregulation in a dose- and time-dependent manner in all sensitive TNBC cells, whereas no alterations in CIP2A expression and p-Akt were noted in bortezomib-resistant cells. Overexpression of CIP2A upregulated p-Akt and protected MDA-MB-231 and MDA-MB-468 cells from bortezomib-induced apoptosis, whereas silencing CIP2A by siRNA overcame the resistance to bortezomib-induced apoptosis in MCF-7 cells. In addition, bortezomib downregulated CIP2A mRNA but did not affect the degradation of CIP2A protein. Furthermore, bortezomib exerted in vivo antitumor activity in HCC-1937 xenografted tumors, but not in MCF-7 tumors. Bortezomib downregulated CIP2A expression in the HCC-1937 tumors but not in the MCF-7 tumors. Importantly, CIP2A expression is readily detectable in tumor samples from TNBC patients.Conclusions: CIP2A is a major determinant mediating bortezomib-induced apoptosis in TNBC cells. CIP2A may thus be a potential therapeutic target in TNBC. ? 2012 Tseng et al.; licensee BioMed Central Ltd.
SDGs

[SDGs]SDG3

Other Subjects
bortezomib; cancerous inhibitor of protein phosphatase 2A; estrogen receptor; messenger RNA; phosphoprotein phosphatase 2A; phosphoprotein phosphatase inhibitor; protein kinase B; small interfering RNA; unclassified drug; antineoplastic agent; autoantigen; boronic acid derivative; bortezomib; estrogen receptor; KIAA1524 protein, human; membrane protein; proteasome inhibitor; protein kinase B; pyrazine derivative; antineoplastic activity; apoptosis; article; cancer cell; cancer cell culture; cell protection; cell strain MCF 7; controlled study; down regulation; drug efficacy; drug mechanism; enzyme inhibition; flow cytometry; gene overexpression; gene silencing; human; human cell; human tissue; immunohistochemistry; in vitro study; in vivo study; mouse; nonhuman; protein degradation; signal transduction; triple negative breast cancer; tumor xenograft; upregulation; Western blotting; animal; breast tumor; dose response; drug effect; drug resistance; drug screening; female; genetics; metabolism; nude mouse; pathology; tumor cell line; Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, Estrogen; Xenograft Model Antitumor Assays
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science